Hematopoietic Stem Cells from Poor and Good Mobilizers Are Qualitatively Equivalent

Overview

Journal Transfusion

Specialty Hematology

Date 2011 Aug 11

PMID 21827503

Citations 3

Authors

Liuyan Jiang

Sunny Malik

Mark Litzow

Dennis Gastineau

Ivana Micallef

Vivek Roy

Lawrence Solberg

Abba C Zubair

Affiliations

Soon will be listed here.

Abstract

Background: Marrow damage from chemo- and radiation therapies has been suggested to affect quality and quantity of hematopoietic stem cell (HSC) products. We tested the hypothesis that CD34+ cells (HSCs) from low mobilizers are qualitatively inferior to HSCs from high mobilizers.

Study Design And Methods: HSC quality was defined by proportion of primitive HSC subsets (CD34+CD38-, CD34+HLA-DR-, and CD34+ in G0 stage of cell cycle), the proportion of HSCs that express CXCR4 and CD26 homing proteins, and days to neutrophil and platelet (PLT) engraftments after transplant. HSC content and CD34 subsets analyses were performed using flow cytometry following the ISHAGE protocol. We evaluated the HSC quantity and quality of 139 autologous filgrastim-mobilized HSC products. Patients were categorized into low, moderate, and high mobilizers if their total HSC collection was less than 3 × 10(6), 3 × 10(6) or more and less than 5 × 10(6), and 5 × 10(6)/kg or more, respectively.

Results: The median number of primitive CD34 subsets increases with increasing HSC numbers and this association was significant (p = 0.001). However, when the ratios of the primitive CD34 subsets to total HSC counts were compared among the mobilization groups, the ratios were not significantly different. Coexpression of neither CD26 nor CXCR4 with CD34 antigen correlated with HSC mobilization. Evaluation of days to neutrophil engraftment among the mobilization groups did not show a significant difference (p = 0.1). However, days to PLT engraftment among the mobilization groups was significantly different (p = 0.05).

Conclusion: The quality of HSCs from low mobilizers was comparable to HSCs from high mobilizers.

Citing Articles

A concise review on factors influencing the hematopoietic stem cell transplantation main outcomes.

Rafiee M, Abbasi M, Rafieemehr H, Mirzaeian A, Barzegar M, Amiri V Health Sci Rep. 2021; 4(2):e282.

PMID: 33977164 PMC: 8103082. DOI: 10.1002/hsr2.282.

Mobilized peripheral blood: an updated perspective.

Karpova D, Rettig M, Dipersio J F1000Res. 2020; 8.

PMID: 32025285 PMC: 6971844. DOI: 10.12688/f1000research.21129.1.

Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation.

Mohty M, Hubel K, Kroger N, Aljurf M, Apperley J, Basak G Bone Marrow Transplant. 2014; 49(7):865-72.

PMID: 24686988 DOI: 10.1038/bmt.2014.39.

References

Zubair A, Zahrieh D, Daley H, Schott D, Gribben J, Alyea E . Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004; 44(2):253-61. DOI: 10.1111/j.1537-2995.2004.00666.x. View

Abrahamsen J, Stamnesfet S, Liseth K, Hervig T, Bruserud O . Large-volume leukapheresis yields more viable CD34+ cells and colony-forming units than normal-volume leukapheresis, especially in patients who mobilize low numbers of CD34+ cells. Transfusion. 2005; 45(2):248-53. DOI: 10.1111/j.1537-2995.2004.04210.x. View

Zubair A, Rymer R, Young J, Keeton U, Befort R, Nolot B . Multiple myeloma patients receiving large volume leukapheresis efficiently yield enough CD34+ cells to allow double transplants. J Clin Apher. 2009; 24(1):6-11. PMC: 2678026. DOI: 10.1002/jca.20190. View

Heissig B, Hattori K, Dias S, Friedrich M, Ferris B, Hackett N . Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell. 2002; 109(5):625-37. PMC: 2826110. DOI: 10.1016/s0092-8674(02)00754-7. View

Richman C, WEINER R, Yankee R . Increase in circulating stem cells following chemotherapy in man. Blood. 1976; 47(6):1031-9. View

Gandhi M, Jestice K, Scott M, Bloxham D, Bass G, Marcus R . The minimum CD34 threshold depends on prior chemotherapy in autologous peripheral blood stem cell recipients. Bone Marrow Transplant. 1999; 23(1):9-13. DOI: 10.1038/sj.bmt.1701530. View

Drake M, Ranaghan L, Morris T, Nolan L, Desai Z, Irvine A . Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol. 1997; 98(3):745-9. DOI: 10.1046/j.1365-2141.1997.2743091.x. View

Prabhash K, Khattry N, Bakshi A, Karandikar R, Joshi A, Kannan S . CD26 expression in donor stem cell harvest and its correlation with engraftment in human haematopoietic stem cell transplantation: potential predictor of early engraftment. Ann Oncol. 2009; 21(3):582-588. DOI: 10.1093/annonc/mdp342. View

Zubair A, Kao G, Daley H, Schott D, FREEDMAN A, Ritz J . CD34(+) CD38(-) and CD34(+) HLA-DR(-) cells in BM stem cell grafts correlate with short-term engraftment but have no influence on long-term hematopoietic reconstitution after autologous transplantation. Cytotherapy. 2006; 8(4):399-407. DOI: 10.1080/14653240600847241. View

10.

Jetmore A, Plett P, Tong X, Wolber F, Breese R, Abonour R . Homing efficiency, cell cycle kinetics, and survival of quiescent and cycling human CD34(+) cells transplanted into conditioned NOD/SCID recipients. Blood. 2002; 99(5):1585-93. DOI: 10.1182/blood.v99.5.1585. View

11.

Levesque J, Takamatsu Y, Nilsson S, Haylock D, Simmons P . Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood. 2001; 98(5):1289-97. DOI: 10.1182/blood.v98.5.1289. View

12.

Bensinger W, DiPersio J, McCarty J . Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant. 2009; 43(3):181-95. DOI: 10.1038/bmt.2008.410. View

13.

Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K . Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol. 1995; 13(10):2547-55. DOI: 10.1200/JCO.1995.13.10.2547. View

14.

Fruehauf S, Ehninger G, Hubel K, Topaly J, Goldschmidt H, Ho A . Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients. Bone Marrow Transplant. 2009; 45(2):269-75. DOI: 10.1038/bmt.2009.142. View

15.

Sutherland D, Anderson L, Keeney M, Nayar R, Chin-Yee I . The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother. 1996; 5(3):213-26. DOI: 10.1089/scd.1.1996.5.213. View

16.

Semerad C, Christopher M, Liu F, Short B, Simmons P, Winkler I . G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood. 2005; 106(9):3020-7. PMC: 1895331. DOI: 10.1182/blood-2004-01-0272. View

17.

Fruehauf S, Haas R, Zeller W, Hunstein W . CD34 selection for purging in multiple myeloma and analysis of CD34+ B cell precursors. Stem Cells. 1994; 12(1):95-102. DOI: 10.1002/stem.5530120116. View

18.

Yu J, Leisenring W, Bensinger W, Holmberg L, Rowley S . The predictive value of white cell or CD34+ cell count in the peripheral blood for timing apheresis and maximizing yield. Transfusion. 1999; 39(5):442-50. DOI: 10.1046/j.1537-2995.1999.39050442.x. View

19.

Levesque J, Hendy J, Takamatsu Y, Williams B, Winkler I, Simmons P . Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol. 2002; 30(5):440-9. DOI: 10.1016/s0301-472x(02)00788-9. View

20.

Fruehauf S, Tricot G . Comparison of unmobilized and mobilized graft characteristics and the implications of cell subsets on autologous and allogeneic transplantation outcomes. Biol Blood Marrow Transplant. 2010; 16(12):1629-48. DOI: 10.1016/j.bbmt.2010.02.002. View